Dr. Greenbaum is a new Associate Attending in the Computational Oncology Service. Dr. Greenbaum’s research seeks to quantify the interaction of tumors with the immune system and to predict immune driven evolution of tumors and viruses. His work utilizes a broad range of tools, from statistical physics and information theory to evolutionary biology. As part of his new role, he will establish a new program in Computational Immuno-Oncology. This program will bring computational approaches to immunotherapy and act as a bridge between the Computational Oncology Service and the Parker Institute for Cancer Immunotherapy, a collaboration of six academic centers including MSK with the goal to use the power of the immune system to fight cancer. Dr. Greenbaum has a PhD in theoretical physics from Columbia University and has trained at Los Alamos National Laboratory and the Institute for Advanced Study. He previously held the role of Associate Professor at Icahn School of Medicine at Mount Sinai in the Departments of Medicine and Oncological Sciences, where he was the founding director of the Center for Computational Immunology. Dr. Greenbaum authored many publications in high-ranking journals and holds several awards including a Phillip A. Sharp Award for Innovation in Collaboration from Stand Up to Cancer, a Pershing Square Sohn Prize, and a Mark Foundation Fellowship.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Benjamin Greenbaum discloses the following relationships and financial interests:
Intellectual Property Rights; Ownership / Equity Interests; Provision of Services
Sibyl Analytics LLC
Fiduciary Role/Position; Ownership / Equity Interests; Provision of Services (uncompensated)
Provision of Services (uncompensated)
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.